{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Unresectable+Hepatocellular+Carcinoma&page=3",
    "query": {
      "condition": "Advanced Unresectable Hepatocellular Carcinoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 151,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Unresectable+Hepatocellular+Carcinoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Unresectable+Hepatocellular+Carcinoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T22:53:19.800Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00006010",
      "title": "Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2001-09",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2016-12-07",
      "last_synced_at": "2026-10-04T22:53:19.800Z",
      "location_count": 16,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 13 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006010"
    },
    {
      "nct_id": "NCT02520141",
      "title": "Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cholangiocarcinoma",
        "Liver and Intrahepatic Bile Duct Carcinoma",
        "Stage III Gallbladder Cancer AJCC v7",
        "Stage III Intrahepatic Cholangiocarcinoma AJCC v7",
        "Stage IIIA Gallbladder Cancer AJCC v7",
        "Stage IIIB Gallbladder Cancer AJCC v7",
        "Stage IV Gallbladder Cancer AJCC v7",
        "Stage IVA Gallbladder Cancer AJCC v7",
        "Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7",
        "Stage IVB Gallbladder Cancer AJCC v7",
        "Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7",
        "Unresectable Gallbladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2015-12-29",
      "completion_date": "2022-06-29",
      "has_results": true,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-10-04T22:53:19.800Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02520141"
    },
    {
      "nct_id": "NCT00004074",
      "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Adult Primary Liver Cancer",
        "Anaplastic Thyroid Cancer",
        "Bone Metastases",
        "Carcinoma of the Appendix",
        "Distal Urethral Cancer",
        "Fallopian Tube Cancer",
        "Gastrinoma",
        "Glucagonoma",
        "Inflammatory Breast Cancer",
        "Insulinoma",
        "Liver Metastases",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Lung Metastases",
        "Male Breast Cancer",
        "Malignant Pericardial Effusion",
        "Malignant Pleural Effusion",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic Parathyroid Cancer",
        "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Newly Diagnosed Carcinoma of Unknown Primary",
        "Occult Non-small Cell Lung Cancer",
        "Pancreatic Polypeptide Tumor",
        "Primary Peritoneal Cavity Cancer",
        "Proximal Urethral Cancer",
        "Pulmonary Carcinoid Tumor",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Adrenocortical Carcinoma",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Anal Cancer",
        "Recurrent Bladder Cancer",
        "Recurrent Breast Cancer",
        "Recurrent Carcinoma of Unknown Primary",
        "Recurrent Cervical Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Esophageal Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Recurrent Gastric Cancer",
        "Recurrent Gastrointestinal Carcinoid Tumor",
        "Recurrent Islet Cell Carcinoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Pancreatic Cancer",
        "Recurrent Parathyroid Cancer",
        "Recurrent Prostate Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Renal Cell Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Small Intestine Cancer",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Thyroid Cancer",
        "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Recurrent Urethral Cancer",
        "Recurrent Vaginal Cancer",
        "Recurrent Vulvar Cancer",
        "Skin Metastases",
        "Small Intestine Adenocarcinoma",
        "Somatostatinoma",
        "Stage III Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage III Adrenocortical Carcinoma",
        "Stage III Bladder Cancer",
        "Stage III Cervical Cancer",
        "Stage III Colon Cancer",
        "Stage III Endometrial Carcinoma",
        "Stage III Esophageal Cancer",
        "Stage III Follicular Thyroid Cancer",
        "Stage III Gastric Cancer",
        "Stage III Malignant Testicular Germ Cell Tumor",
        "Stage III Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Pancreatic Cancer",
        "Stage III Papillary Thyroid Cancer",
        "Stage III Prostate Cancer",
        "Stage III Rectal Cancer",
        "Stage III Renal Cell Cancer",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Vaginal Cancer",
        "Stage III Vulvar Cancer",
        "Stage IIIA Anal Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIB Anal Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Adrenocortical Carcinoma",
        "Stage IV Anal Cancer",
        "Stage IV Bladder Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Endometrial Carcinoma",
        "Stage IV Esophageal Cancer",
        "Stage IV Follicular Thyroid Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IV Papillary Thyroid Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Cervical Cancer",
        "Stage IVA Vaginal Cancer",
        "Stage IVB Cervical Cancer",
        "Stage IVB Vaginal Cancer",
        "Stage IVB Vulvar Cancer",
        "Thyroid Gland Medullary Carcinoma",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer",
        "Urethral Cancer Associated With Invasive Bladder Cancer",
        "WDHA Syndrome"
      ],
      "interventions": [
        {
          "name": "recombinant interleukin-12",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ABI-007/carboplatin/trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "1999-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-10-04T22:53:19.800Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004074"
    },
    {
      "nct_id": "NCT01015833",
      "title": "Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Adult Hepatocellular Carcinoma",
        "Recurrent Hepatocellular Carcinoma",
        "Stage III Hepatocellular Carcinoma AJCC v7",
        "Stage IIIA Hepatocellular Carcinoma AJCC v7",
        "Stage IIIB Hepatocellular Carcinoma AJCC v7",
        "Stage IIIC Hepatocellular Carcinoma AJCC v7",
        "Stage IV Hepatocellular Carcinoma AJCC v7",
        "Stage IVA Hepatocellular Carcinoma AJCC v7",
        "Stage IVB Hepatocellular Carcinoma AJCC v7",
        "Unresectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 356,
      "start_date": "2010-02-15",
      "completion_date": "2018-08-15",
      "has_results": true,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-10-04T22:53:19.800Z",
      "location_count": 659,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 404 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01015833"
    },
    {
      "nct_id": "NCT00021047",
      "title": "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Extrahepatic Bile Duct Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Liver Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "epirubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-07",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-10-04T22:53:19.800Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Portsmouth, Virginia",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Portsmouth",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00021047"
    },
    {
      "nct_id": "NCT01507168",
      "title": "A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "GC33",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2012-02-02",
      "completion_date": "2015-08-20",
      "has_results": false,
      "last_update_posted_date": "2020-04-03",
      "last_synced_at": "2026-10-04T22:53:19.800Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Bethesda, Maryland • Detroit, Michigan + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01507168"
    },
    {
      "nct_id": "NCT01766219",
      "title": "CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Primary Cholangiocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Cholangiocarcinoma of the Extrahepatic Bile Duct",
        "Cholangiocarcinoma of the Gallbladder",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Metastatic Extrahepatic Bile Duct Cancer",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Unresectable Extrahepatic Bile Duct Cancer"
      ],
      "interventions": [
        {
          "name": "6,8-bis(benzylthio)octanoic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2013-05",
      "completion_date": "2018-05-18",
      "has_results": true,
      "last_update_posted_date": "2019-05-15",
      "last_synced_at": "2026-10-04T22:53:19.800Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01766219"
    },
    {
      "nct_id": "NCT01899261",
      "title": "Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adult Hepatocellular Carcinoma",
        "Advanced Adult Hepatocellular Carcinoma",
        "Localized Non-Resectable Adult Liver Carcinoma",
        "Recurrent Adult Liver Carcinoma"
      ],
      "interventions": [
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-10-07",
      "completion_date": "2019-05",
      "has_results": true,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-04T22:53:19.800Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01899261"
    },
    {
      "nct_id": "NCT03298451",
      "title": "Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab (Regimen 1)",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab (Regimen 2)",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab (Regimen 1)",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab (Regimen 2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 1324,
      "start_date": "2017-10-11",
      "completion_date": "2027-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-10-04T22:53:19.800Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03298451"
    },
    {
      "nct_id": "NCT00054262",
      "title": "T900607 in Treating Patients With Unresectable Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "T900607",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospitals Seidman Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-11",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2013-07-18",
      "last_synced_at": "2026-10-04T22:53:19.800Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00054262"
    }
  ]
}